Print This Page

The market for wound care exceeds $7 billion annually, yet no product or treatment currently exists that consistently accelerates healing rates, leaving millions of patients suffering with chronic wounds — in many cases losing the battle to amputation and even death. Much of the problem lies with the fact that healing relies heavily on the presence of an energy molecule called adenosine triphosphate (ATP). In fact, most wound care products themselves rely on the presence of energy in order to work. Novera is developing a revolutionary topical drug that accelerates the wound healing process, using its patent pending method of delivering ATP directly to cells.